Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis

English version České info

Alexandra Snyder and colleagues reveal the complex nature of the immune response to checkpoint blockade in metastatic urothelial cancer patients. Time-varying effects of somatic mutation load on survival are reported.

Vyšlo v časopise: Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis. PLoS Med 14(5): e32767. doi:10.1371/journal.pmed.1002309
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1002309

Souhrn

Zdroje

1. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515: 558–562. doi: 10.1038/nature13904 25428503

2. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387: 1909–1920. doi: 10.1016/S0140-6736(16)00561-4 26952546

3. Postow MA, Yuan J, Kitano S, Lesokhin AM, Wolchok JD. Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma. Methods Mol Biol. 2014;1102: 83–95. doi: 10.1007/978-1-62703-727-3_6 24258975

4. Robins HS, Campregher PV, Srivastava SK, Wacher A, Turtle CJ, Kahsai O, et al. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood. 2009;114: 4099–4107. doi: 10.1182/blood-2009-04-217604 19706884

5. Lefranc M-P, Giudicelli V, Duroux P, Jabado-Michaloud J, Folch G, Aouinti S, et al. IMGT®, the international ImMunoGeneTics information system® 25 years on. Nucleic Acids Res. 2015;43: D413–22. doi: 10.1093/nar/gku1056 25378316

6. Wu D, Emerson RO, Sherwood A, Loh ML, Angiolillo A, Howie B, et al. Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH. Clin Cancer Res. 2014;20: 4540–4548. doi: 10.1158/1078-0432.CCR-13-3231 24970842

7. Hsu MS, Sedighim S, Wang T, Antonios JP, Everson RG, Tucker AM, et al. TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination. Cancer Immunol Res. 2016;4: 412–418. doi: 10.1158/2326-6066.CIR-15-0240 26968205

8. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515: 568–571. doi: 10.1038/nature13954 25428505

9. DeWitt WS, Emerson RO, Lindau P, Vignali M, Snyder TM, Desmarais C, et al. Dynamics of the cytotoxic T cell response to a model of acute viral infection. J Virol. 2015;89: 4517–4526. doi: 10.1128/JVI.03474-14 25653453

10. Rizvi N., Hellmann M, Snyder, Et al A. Mutational Landscape Determines Sensitivity to Programmed Cell Death-1 Blockade in Non-Small Cell Lung Cancer. Science. 2015;

11. Kauffmann A, Rosselli F, Lazar V, Winnepenninckx V, Mansuet-Lupo A, Dessen P, et al. High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene. 2008;27: 565–573. doi: 10.1038/sj.onc.1210700 17891185

12. Tuteja N, Singh MB, Misra MK, Bhalla PL, Tuteja R. Molecular mechanisms of DNA damage and repair: progress in plants. Crit Rev Biochem Mol Biol. 2001;36: 337–397. doi: 10.1080/20014091074219 11563486

13. Sonpavde G, Pond GR, Rosenberg JE, Bajorin DF, Choueiri TK, Necchi A, et al. Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. J Urol. 2016;195: 277–282. doi: 10.1016/j.juro.2015.07.111 26292040

14. Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17: 3173–3181. doi: 10.1200/JCO.1999.17.10.3173 10506615

15. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21: 137–148. doi: 10.1016/j.immuni.2004.07.017 15308095

16. Cha E, Klinger M, Hou Y, Cummings C, Ribas A, Faham M, et al. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med. 2014;6: 238ra70. doi: 10.1126/scitranslmed.3008211 24871131

17. Alioto TS, Buchhalter I, Derdak S, Hutter B, Eldridge MD, Hovig E, et al. A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. Nat Commun. 2015;6: 10001. doi: 10.1038/ncomms10001 26647970

18. Qiu P, Pang L, Arreaza G, Maguire M, Chang KC, Marton MJ, et al. Data Interoperability of Whole Exome Sequencing (WES) Based Mutational Burden Estimates from Different Laboratories. Int J Mol Sci. 2016;17.

19. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39: 782–795. doi: 10.1016/j.immuni.2013.10.003 24138885

20. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27: 1739–1740. doi: 10.1093/bioinformatics/btr260 21546393

21. Tirosh I, Izar B, Prakadan SM, Wadsworth MH 2nd, Treacy D, Trombetta JJ, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016;352: 189–196. doi: 10.1126/science.aad0501 27124452

22. Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350: 207–211. doi: 10.1126/science.aad0095 26359337

23. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371: 2189–2199. doi: 10.1056/NEJMoa1406498 25409260